文献速递白血病

瑞典CML注册研究:临床试验外成功停用酪氨酸激酶抑制剂

Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
PubMed 文献 · Br J Haematol · 2021-03-30

该回顾性研究利用瑞典CML注册数据,分析2007-2012年诊断的584例慢性期CML患者中548例有TKI停药信息的患者。中位随访9年,128例(23%)因获得深度分子学反应(DMR)停药,107例(20%)因其他原因停药。结论:临床实践中TKI停药常见且可行,成功率可能与临床试验内相当。

要点

  • 临床实践中因DMR停用TKI可行,约半数患者需重启治疗
  • 停药前TKI治疗时长和研究外使用二代TKI比例略高,可能影响结局

核心结论

  • 临床实践中CML患者TKI停药常见且可行,成功率可能与临床试验内相当。

研究设计与样本

  • 回顾性研究,利用瑞典CML注册数据,2007-2012年诊断的584例慢性期CML患者中548例有TKI停药可评估信息,中位随访9年。

主要发现

  • 128例(23%)因获得DMR停用TKI至少1个月,107例(20%)因其他原因停药。
  • 研究外停药者停药前TKI治疗时长更长,使用二代TKI比例略高。

临床怎么用

  • 临床实践中可考虑对获得DMR的CML患者停用TKI,但需密切监测并在需要时重启治疗。

局限性

  • 回顾性研究设计,停药决策和监测可能受非研究因素影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines support such procedure in clinical routine, data on TKI stopping outside clinical trials are limited. In this retrospective study utilising the Swedish CML registry, we examined TKI discontinuation in a population-based setting. Out of 584 patients diagnosed with chronic-phase CML (CML-CP) in 2007-2012, 548 had evaluable information on TKI discontinuation. With a median follow-up of nine years from diagnosis, 128 (23%) discontinued TKI therapy (≥1 month) due to achieving a DMR (deep molecular response) and 107 (20%) due to other causes (adverse events, allogeneic stem cell transplant, pregnancy, etc). Among those stopping in DMR, 49% re-initiated TKI treatment (median time to restart 4·8 months). In all, 38 patients stopped TKI within a clinical study and 90 outside a study. After 24 months 41·1% of patients discontinuing outside a study had re-initiated TKI treatment. TKI treatment duration pre-stop was longer and proportion treated with second-generation TKI slightly higher outside studies, conceivably affecting the clinical outcome. In summary we show that TKI discontinuation in CML in clinical practice is common and feasible and may be just as successful as when performed within a clinical trial.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Flygt H, Sandin F, Dahlén T, et al. Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry. Br J Haematol. 2021. PMID: 33782950. doi:10.1111/bjh.17392

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。